Janssen Presents Results of Nipocalimab (M281) in P-II Vivacity-MG Study for Adults with Generalized Myasthenia Gravis at AAN2021
Janssen Reports Updated Data of Amivantamab + Lazertinib in P-I CHRYSALIS Study for EGFR-Mutated NSCLC
Shots:
- The P-II Vivacity-MG study involves assessing the safety, tolerability, efficacy, PK, PD, and immunogenicity of nipocalimab in addition to SoC vs PBO in a ratio (1:1:1:1:1) in 68 patients with gMG
- The 1EPs of the study include safety, tolerability, and efficacy assessed by (MG-ADL) ADL score. The 2EPs includes the efficacy as measured by changes in QMG score and revised MG-QoL15 scale from baseline, PK, and PD activity as measured by effects on total serum IgG concentrations, safety and tolerability
- Nipocalimab is a high affinity, fully human, aglycosylated, effectorless IgG1 anti-FcRn mAb and has been received ODD from US FDA for MG
Click here to read full press release/ article | Ref: PRNewswire | Image: Michigan Health Blog